{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:09:16Z","timestamp":1781669356758,"version":"3.54.5"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Testosterone therapy (TT) is widely prescribed for hypogonadism. It leads to symptomatic improvement but as with any medication carries risks, as outlined in US Food and Drug Administration (FDA) labels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The current study analyzes TT lawsuits against providers to identify litigation patterns, adverse outcomes, and their implications, informing clinical practices for improved patient safety and reduced legal risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a comprehensive search of the Westlaw and LexisNexis legal databases, covering cases from 2000 to 2024, using the keywords \u201ctestosterone\u201d combined with \u201cMD,\u201d \u201cDO,\u201d or \u201cDr.\u201d We identified cases, excluding those against \u201cCommissioner of Social Security\u201d or \u201c, Inc.\u201d entities, to narrow the focus to individual healthcare providers. A total of 306 cases from Westlaw and 683 from LexisNexis were reviewed. After applying the inclusion criteria, 25 cases were selected for final analysis, with data extracted on treatment type, adverse outcomes, provider specialty, and court rulings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>We sought to characterize common provider specialties, treatment patterns, adverse outcomes, and legal decisions associated with TT-related litigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 25 cases involving TT, most involved internal medicine providers (12 cases, 48%), followed by family medicine (4 cases, 16%) and urology (2 cases, 8%). There were 3 cases from 2000 to 2010 and 22 cases from 2011 to 2023. The primary harms included withholding TT (10 cases, 40%), prostate cancer (4 cases, 16%), death (3 cases, 12%), cardiac events (3 cases, 12%), psychiatric effects (2 cases, 8%), and less frequent adverse outcomes, each observed in 1 case (4%), included virilization in female patients and infections or abscesses. Gels (6 cases, 24%) and testosterone injections (5 cases, 20%) were the most frequently involved treatments. Court rulings favored defendants in 9 cases (36%) and plaintiffs in 3 cases (12%). Nine cases (36%) were related to violations of the Eighth Amendment in incarcerated individuals. Seven cases (28%) remain unresolved.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Litigation related to TT often centers on nontreatment and oncologic complications, underscoring the need for guideline-concordant prescribing and thorough risk communication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>The strengths of this study include a two-decade review and focus on provider-level litigation patterns. Limitations include exclusion of settled or sealed cases, and absence of financial data or patient demographics. The small sample size may also limit generalizability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TT-related lawsuits are increasing, particularly among nonurologists, highlighting the importance of documentation, risk stratification, and communication to reduce legal exposure and improve patient care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf181","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:35:05Z","timestamp":1751960105000},"page":"1572-1578","source":"Crossref","is-referenced-by-count":1,"title":["Testosterone therapy and lawsuits against prescribers: a legal case review from 2000 to 2024"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-2646","authenticated-orcid":false,"given":"Ashkan","family":"Pourabhari Langroudi","sequence":"first","affiliation":[{"name":"Department of Urology, School of Medicine, Stanford University , Stanford, CA , 94305,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satvir","family":"Basran","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Stanford University , Stanford, CA , 94305,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby L","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Stanford University , Stanford, CA , 94305,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-6412","authenticated-orcid":false,"given":"Fausto","family":"Negri","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Stanford University , Stanford, CA , 94305,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stinson","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Stanford University , Stanford, CA , 94305,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , Tainan , 70403,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Saabye Simonsen","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Stanford University , Stanford, CA , 94305,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giuduce","sequence":"additional","affiliation":[{"name":"Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, \u201cSapienza\u201d University of Rome , Rome , 00161,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-0141","authenticated-orcid":false,"given":"Michael L","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Stanford University , Stanford, CA , 94305,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,3]]},"reference":[{"issue":"2","key":"2025090408013586900_ref1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and Management of Testosterone Deficiency: AUA Guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"2025090408013586900_ref2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0970-1591.124197","article-title":"Risks of testosterone replacement therapy in men","volume":"30","author":"Osterberg","year":"2014","journal-title":"Indian J Urol"},{"issue":"1","key":"2025090408013586900_ref3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.13589","article-title":"The state of testosterone therapy since the FDA's 2015 labelling changes: indications and cardiovascular risk","volume":"89","author":"Miner","year":"2018","journal-title":"Clin Endocrinol"},{"key":"2025090408013586900_ref4","article-title":"FDA Drug Safety Communication: FDA Cautions about Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and Stroke with Use"},{"key":"2025090408013586900_ref5","article-title":"FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use\u201402\/28\/2025 update"},{"issue":"2","key":"2025090408013586900_ref6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2025090408013586900_ref7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"15","key":"2025090408013586900_ref8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1001\/archinte.166.15.1660","article-title":"Low serum testosterone and mortality in male veterans","volume":"166","author":"Shores","year":"2006","journal-title":"Arch Intern Med"},{"issue":"6","key":"2025090408013586900_ref9","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis","volume":"95","author":"Fernandez-Balsells","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025090408013586900_ref10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"2025090408013586900_ref11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA."},{"issue":"1","key":"2025090408013586900_ref12","doi-asserted-by":"publisher","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"2025090408013586900_ref13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.urology.2021.12.030","article-title":"Medical malpractice lawsuits involving urology trainees","volume":"166","author":"Golan","year":"2022","journal-title":"Urology."},{"key":"2025090408013586900_ref14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.urology.2022.04.037","article-title":"Medical malpractice lawsuits involving urology trainees: Spain's setting","volume":"166","author":"Martin-Fumado","year":"2022","journal-title":"Urology."},{"issue":"3","key":"2025090408013586900_ref15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1464-410x.2000.00840-2.x","article-title":"Malpractice risks for urologists","volume":"86","author":"Preston","year":"2000","journal-title":"BJU Int"},{"key":"2025090408013586900_ref16","article-title":"Ruling","author":"Cornell Law School Legal Information Institute"},{"key":"2025090408013586900_ref17","article-title":"Pleadings and notions\u2014module 2 of 5","author":"LawShelf"},{"key":"2025090408013586900_ref18","volume-title":"Estelle v. Gamble: defining prisoners\u2019 rights to medical care","author":"Von Wooding"},{"key":"2025090408013586900_ref19","article-title":"Deliberate indifference | Definition, standard & examples","author":"Langford"},{"key":"2025090408013586900_ref20","article-title":"Summary judgment","author":"Cornell Law School Legal Information Institute"},{"key":"2025090408013586900_ref21","article-title":"Cornell Law School Legal Information Institute.Wrongful death"},{"key":"2025090408013586900_ref22","author":"Murdock"},{"issue":"4","key":"2025090408013586900_ref23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41443-023-00709-1","article-title":"Trends in testosterone prescription during the release of society guidelines","volume":"36","author":"Sellke","year":"2024","journal-title":"Int J Impot Res"},{"issue":"6","key":"2025090408013586900_ref24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.21037\/tau.2016.09.08","article-title":"Impact of recent FDA ruling on testosterone replacement therapy (TRT)","volume":"5","author":"Metzger","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"3","key":"2025090408013586900_ref25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3803\/EnM.2020.760","article-title":"Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations","volume":"35","author":"Al-Sharefi","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"2025090408013586900_ref26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5534\/wjmh.190166","article-title":"A national analysis of temporal changes in prescribing of testosterone replacement therapy considering methods of delivery and government regulation","volume":"39","author":"Morton","year":"2021","journal-title":"World J Mens Health"},{"issue":"6","key":"2025090408013586900_ref27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5489\/cuaj.6892","article-title":"Canadian trends in testosterone therapy","volume":"15","author":"Ory","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"2025090408013586900_ref28","article-title":"DEA regs bulk up with 2014 anabolic steroid control law additions","author":"Houck"},{"key":"2025090408013586900_ref29","article-title":"Practitioners and prescriptive authority","volume-title":"StatPearls","author":"Zhang","year":"2025"},{"issue":"4","key":"2025090408013586900_ref30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamainternmed.2022.7008","article-title":"Direct-to-consumer low-testosterone clinics\u2014where is the Federation of State Medical Boards?","volume":"183","author":"Woloshin","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2025090408013586900_ref31","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/jamainternmed.2022.4928","article-title":"Guideline-discordant care among direct-to-consumer testosterone therapy platforms","volume":"182","author":"Dubin","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025090408013586900_ref32","article-title":"Third temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications","author":"Drug Enforcement Administration and Health and Human Services"},{"issue":"5","key":"2025090408013586900_ref33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","article-title":"Testosterone therapy in men with prostate cancer","volume":"69","author":"Kaplan","year":"2016","journal-title":"Eur Urol"},{"issue":"41","key":"2025090408013586900_ref34","doi-asserted-by":"publisher","first-page":"E1286","DOI":"10.1503\/cmaj.170683","article-title":"Testosterone use causing erythrocytosis","volume":"189","author":"Cervi","year":"2017","journal-title":"CMAJ."},{"issue":"3","key":"2025090408013586900_ref35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/med.0b013e32832b6348","article-title":"Temporal trends in testosterone levels and treatment in older men","volume":"16","author":"Travison","year":"2009","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"2025090408013586900_ref36","doi-asserted-by":"publisher","first-page":"E407","DOI":"10.1001\/amajethics.2023.407","article-title":"Gender-affirming care, incarceration, and the Eighth Amendment","volume":"25","author":"Aldrich","year":"2023","journal-title":"AMA J Ethics"},{"key":"2025090408013586900_ref37","article-title":"Testosterone replacement therapy needed and potential harm","author":"Ragatz"},{"issue":"8","key":"2025090408013586900_ref38","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.21037\/tau-21-350","article-title":"Barriers to receiving testosterone replacement therapy in the community during COVID-19 pandemic","volume":"10","author":"Troesch","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"Suppl 1(2)","key":"2025090408013586900_ref39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7417\/CT.2025.5184","article-title":"Legal considerations in bioidentical hormone replacement therapy: anticipating future challenges in medical liability","volume":"176","author":"Del Duca","year":"2025","journal-title":"Clin Ter"},{"key":"2025090408013586900_ref40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pec.2022.10.003","article-title":"Characterizing patient attitudes and beliefs towards testosterone therapy in Veterans Affairs: a qualitative study","volume":"106","author":"Engle","year":"2023","journal-title":"Patient Educ Couns"},{"issue":"3","key":"2025090408013586900_ref41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.pec.2014.07.017","article-title":"Understanding patient perceptions of shared decision making","volume":"96","author":"Shay","year":"2014","journal-title":"Patient Educ Couns"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/9\/1572\/63925029\/qdaf181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/9\/1572\/63925029\/qdaf181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:01:55Z","timestamp":1756987315000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/9\/1572\/8221479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,3]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,8,3]]},"published-print":{"date-parts":[[2025,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf181","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,3]]}}}